EGFR and lung adenocarcinoma: Several large randomized phase III clinical trials, such as First‐SIGNA,9 WJTOG3405,10 NEJ002,11 OPTIMAL,12 ENSURE,13 and EURTAC,14 demonstrated that the curative effect of targeted therapy for lung adenocarcinoma with EGFR sensitive mutations is significantly better than that with traditional chemotherapy.